| Objective: With the increasing economic and social development,Chronic liver diseases(CLD)has become a serious threat to global health.Many gene association studies attempted to explore the potential association between transmembrane 6 superfamily member 2(TM6SF2)polymorphism and CLD.However,the results of these studies are not consistent.Therefore,this meta-analysis comprehensively analyzed the effect of TM6SF2 rs58542926 polymorphism on CLD susceptibility in the population.Methods: Through the systematic search of PubMed,EMBASE,Cochrane Library,CNKI,Wanfang,VIP and other databases,we found the related literature of TM6SF2 rs58542926 polymorphism and CLD susceptibility.The data of the first author,time of publication,country of study object,race of study object,sample size of case group and control group,method of gene detection,genotype distribution and allele frequency of TM6SF2 polymorphism in case group and control group were extracted.For each study,the probability value of Hardy Weinberg equilibrium(HWE)was calculated.All the included studies were analyzed and evaluated.Stata 13.0 and Revman 5.2 were used for combined analysis.Results: Finally,25 articles were included.A total of 21384 cases were included,including 12239 cases in the case group and 9145 cases in the controlgroup.12 of the literatures included were Caucasian,10 were Asian and 3 were mixed race;12 of the literatures included were nadlf,8 were cirrhosis,6 were CHB,4 were HCC,2 were ALD and 3 were CHC.The NOS of all the included literatures were higher than or equal to 7 points.At the same time,all the documents included are in line with the Harwin balance.Meta results showed that TM6SF2 rs58542926 polymorphism increased CLD risk in the general population,Caucasian population and Asian population [Overall Allelic model(T vs.C):OR=1.46,95% CI:1.34-1.58,P < 0.0001;dominant gene(CT+TT vs.CC):OR=1.43,95% CI:1.31-1.56,P < 0.0001、recessive gene(TT vs.CC+CT): OR=2.94,95% CI : 2.05-4.20,P < 0.0001;overdominant gene(CC+TT vs.CT):OR=0.74,95% CI:0.68-0.81,P < 0.0001;Homozygote model(TT vs.CC):OR=3.14,95% CI:2.19-4.49,P < 0.0001;Heterozygote model(CT vs.CC):OR=1.36,95% CI:1.25-1.49,P < 0.0001;Caucasian(T vs.C:OR=1.32,95% CI:1.11-1.58,P= 0.002;CT+TT vs.CC:OR=1.30,95% CI:1.09-1.55,P < 0.0001;TT vs.CC+CT:OR=2.85,95% CI:1.85-4.37;P < 0.0001;TT vs.CC:OR=3.01,95% CI:1.96-4.63,P < 0.0001;CT vs.CC:OR=1.27,95% CI:1.13-1.43,P < 0.0001;CC+TT vs.CT:OR=1.25,95% CI:1.11-1.40,P < 0.0001);Asian population(T vs.C:OR=1.45,95%CI:1.27-1.66,P < 0.0001;CT+TT vs.CC:OR=1.45,95% CI:1.27-1.67,P < 0.0001;TT vs.CC+CT:OR=2.29,95% CI:1.07-4.87;P < 0.0001;TT vs.CC:OR=2.48,95% CI:1.17-5.26,p = 0.018;CT vs.CC:OR=1.42,95% CI:1.23-1.64,P < 0.0001;CC+TT vs.CT:OR=1.41,95% CI:1.22-1.63,P < 0.0001)].Similarly,TM6SF2 rs58542916 increases the risk of NAFLD,HCC,and cirrhosis [NAFLD(T vs.C:OR=1.87,95% CI:1.61-2.17,P < 0.0001;CT+TT vs.CC:OR=1.85,95% CI:1.57-2.16,P < 0.0001;TT vs.CC+CT:OR=5.20,95% CI:2.43-11.13;P < 0.0001;TT vs.CC:OR=5.69,95% CI:2.65-12.2,P < 0.0001;CT vs.CC:OR=1.73,95% CI:1.47-2.03,P < 0.0001;CC+TT vs.CT:OR=1.69,95% CI:1.44-1.98,P < 0.0001);HCC(T vs.C:OR=1.74,95% CI:1.26-2.39,P= 0.001;CT+TT vs.CC:OR=1.73,95% CI:1.20-2.49,P= 0.003;TT vs.CC+CT:OR=3.29,95% CI:1.92-5.66;P < 0.0001;TT vs.CC:OR=3.60,95% CI:2.10-6.18,P < 0.0001;CT vs.CC:OR=1.60,95% CI:1.12-2.30,P=0.01;CC+TT vs.CT:OR=1.55,95% CI:1.10-2.18,P=0.013);Cirrhosis(T vs.C:OR=1.38,95% CI:1.11-1.72,P= 0.004;CT+TT vs.CC:OR=1.38,95% CI:1.10-1.74,P= 0.006;TT vs.CC+CT:OR=1.79,95% CI:0.50-6.37;P=0.369;TT vs.CC:OR=1.85,95% CI:0.52-6.63,P=0.342;CT vs.CC:OR=1.36,95% CI:1.08-1.72,P=0.009;CC+TT vs.CT:OR=1.36,95% CI:1.08-1.71,P=0.010)].There was no significant correlation between ALD,CHB and CHC and TM6SF2 rs58542916.No changes in the results were observed in the sensitivity analysis of each model and subgroup.Conclusion: TM6SF2 rs58542926 polymorphism may affect the individual susceptibility to CLD in Asians and Caucasians;TM6SF2rs58542926 polymorphism increases the risk of HCC,cirrhosis and NAFLD,but has no significant correlation with ALD,CHB and CHC. |
PDF Full Text Request